It isn’t easy to get pharmaceutical companies interested in developing treatments for a tiny population of patients. The suggestion from experts at this week’s Oxford-Harrington Rare Disease Centre Symposium: find an approach that also addresses a more common disease. Ayisha Sharma has the details here.
